- Home
- SCD vs IMMP Comparison
SCD vs IMMP Comparison
Compare SCD & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCD
- IMMP
- Stock Information
- Founded
- SCD 2003
- IMMP 1987
- Country
- SCD United States
- IMMP Australia
- Employees
- SCD N/A
- IMMP N/A
- Industry
- SCD Trusts Except Educational Religious and Charitable
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- SCD Finance
- IMMP Health Care
- Exchange
- SCD Nasdaq
- IMMP Nasdaq
- Market Cap
- SCD 264.7M
- IMMP 251.8M
- IPO Year
- SCD N/A
- IMMP N/A
- Fundamental
- Price
- SCD $15.06
- IMMP $2.04
- Analyst Decision
- SCD
- IMMP Buy
- Analyst Count
- SCD 0
- IMMP 1
- Target Price
- SCD N/A
- IMMP $7.00
- AVG Volume (30 Days)
- SCD 62.6K
- IMMP 179.2K
- Earning Date
- SCD 01-01-0001
- IMMP 10-10-2025
- Dividend Yield
- SCD 9.63%
- IMMP N/A
- EPS Growth
- SCD N/A
- IMMP N/A
- EPS
- SCD N/A
- IMMP N/A
- Revenue
- SCD N/A
- IMMP $3,306,742.00
- Revenue This Year
- SCD N/A
- IMMP $16.82
- Revenue Next Year
- SCD N/A
- IMMP N/A
- P/E Ratio
- SCD N/A
- IMMP N/A
- Revenue Growth
- SCD N/A
- IMMP 31.28
- 52 Week Low
- SCD $11.33
- IMMP $1.32
- 52 Week High
- SCD $15.87
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- SCD 34.50
- IMMP 64.15
- Support Level
- SCD $14.83
- IMMP $2.02
- Resistance Level
- SCD $15.63
- IMMP $2.28
- Average True Range (ATR)
- SCD 0.24
- IMMP 0.12
- MACD
- SCD -0.08
- IMMP 0.01
- Stochastic Oscillator
- SCD 23.74
- IMMP 58.49
About SCD LMP Capital and Income Fund Inc.
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.